HealthStream Announces Second Quarter 2025 Results
Second Quarter 2025
-
Revenues of
in the second quarter of 2025, up$74.4 million 4.0% from in the second quarter of 2024, setting a new Company record for quarterly revenue$71.6 million -
Operating income of
in the second quarter of 2025, up$5.9 million 33.4% from in the second quarter of 2024$4.4 million -
Net income of
in the second quarter of 2025, up$5.4 million 29.3% from in the second quarter of 2024$4.2 million -
Earnings per share (EPS) of
per share (diluted) in the second quarter of 2025, up from$0.18 per share (diluted) in the second quarter of 2024$0.14 -
Adjusted EBITDA1 of
in the second quarter of 2025, up$17.6 million 11.3% from in the second quarter of 2024$15.8 million -
Board of Directors authorized a share repurchase program on May 8, 2025 to repurchase up to
of outstanding shares of common stock, with$25.0 million repurchased during the second quarter$18.1 million -
Board of Directors declared a quarterly cash dividend of
per share, payable on August 29, 2025 to holders of record on August 18, 2025$0.03 1
1 Adjusted EBITDA is a non-GAAP financial measure. A reconciliation of adjusted EBITDA to net income and disclosure regarding why we believe adjusted EBITDA provides useful information to investors is included later in this release. |
Financial Results:
Second Quarter 2025 Compared to Second Quarter 2024
Revenues for the second quarter of 2025 increased by
Operating income was
Net income was
Adjusted EBITDA was
At June 30, 2025, the Company had cash, cash equivalents, and marketable securities of
Year-to-Date 2025 Compared to Year-to-Date 2024
For the six months ended June 30, 2025, revenues were
Other Business Updates
On May 8, 2025, the Company announced a share repurchase program approved by the Board of Directors under which the Company is authorized to repurchase up to
On August 4, 2025, the Board of Directors approved a quarterly cash dividend under the Company's dividend policy of
Financial Outlook for 2025
The Company is updating its guidance for 2025 for certain of the measures set forth below. For a reconciliation of projected adjusted EBITDA, a non-GAAP financial measure defined later in this release, to projected net income (the most comparable GAAP measure) for 2025, see the table included on page nine of this release.
Ìý |
Ìý |
Full Year 2025 Guidance |
||||||||
Ìý |
Ìý |
Ìý |
Low |
Ìý |
Ìý |
Ìý |
Ìý |
High |
Ìý |
Ìý |
Revenue |
Ìý |
$ |
297.5 |
Ìý |
- |
Ìý |
$ |
303.5 |
Ìý |
million |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Net Income1 |
Ìý |
$ |
19.5 |
Ìý |
- |
Ìý |
$ |
22.4 |
Ìý |
million |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Adjusted EBITDA |
Ìý |
$ |
68.5 |
Ìý |
- |
Ìý |
$ |
72.5 |
Ìý |
million |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Capital Expenditures |
Ìý |
$ |
31.0 |
Ìý |
- |
Ìý |
$ |
34.0 |
Ìý |
million |
Ìý
1 Previous expected Net Income guidance range was |
The Company’s guidance for 2025, as set forth above, reflects the Company’s assumptions regarding, among other things, expectations for new sales and renewals. This consolidated guidance does not include the impact of any acquisitions or dispositions that we may complete during 2025, gains or losses from changes in the fair value of non-marketable equity investments, or impairment of long-lived assets.
Commenting on HealthStream’s results, Robert A. Frist, Jr., Chief Executive Officer, HealthStream, said, “Our financial performance in the second quarter of 2025 showed year-over-year increases in each of the major categories we highlight in our earnings release, including record quarterly revenues of
A conference call with Robert A. Frist, Jr., Chief Executive Officer, Scott A. Roberts, Chief Financial Officer and Senior Vice President, and Mollie Condra, Head, Investor Relations and Communications, will be held on Tuesday, August 5, 2025, at 9:00 a.m. (ET). Participants may access the conference call live via webcast using this link: . To participate via telephone, please register in advance using this link: . A replay of the conference call and webcast will be archived on the Company’s website in the Investor Relations section under “Events & Presentations.�
Use of Non-GAAP Financial Measures
This press release presents adjusted EBITDA, a non-GAAP financial measure used by management in analyzing the Company’s financial results and ongoing operational performance. In order to better assess the Company’s financial results, management believes that net income before interest, income taxes, stock-based compensation, depreciation and amortization, and changes in fair value of, including gains (losses) on the sale of, non-marketable equity investments (“adjusted EBITDA�) is a useful measure for evaluating the operating performance of the Company because adjusted EBITDA reflects net income adjusted for certain GAAP accounting, non-cash, and/or non-operating items which may not, in any such case, fully reflect the underlying operating performance of our business. We believe that adjusted EBITDA is useful to investors to assess the Company’s ongoing operating performance and to compare the Company’s operating performance between periods. In addition, certain short-term cash incentive bonuses and performance-based equity awards are based on the achievement of adjusted EBITDA (as defined in applicable bonus and equity grant documentation) targets.
Adjusted EBITDA is a non-GAAP financial measure and should not be considered as a measure of financial performance under GAAP. Because adjusted EBITDA is not a measurement determined in accordance with GAAP, adjusted EBITDA is susceptible to varying calculations. Accordingly, adjusted EBITDA, as presented, may not be comparable to other similarly titled measures of other companies and has limitations as an analytical tool.
This non-GAAP financial measure should not be considered a substitute for, or superior to, measures of financial performance, which are prepared in accordance with GAAP. Investors are encouraged to review the reconciliations of adjusted EBITDA to net income (the most comparable GAAP measure), which is set forth below in this release.
About HealthStream
HealthStream (Nasdaq: HSTM) is the healthcare industry’s largest ecosystem of platform-delivered workforce solutions that empowers healthcare professionals to do what they do best: deliver excellence in patient care. For more information about HealthStream, visit or call 615-301-3100.
Ìý HEALTHSTREAM, INC. Condensed Consolidated Statements of Income (In thousands, except per share data) (Unaudited) Ìý |
||||||||||||||||
Ìý |
Ìý |
Three Months Ended |
Ìý |
Ìý |
Six Months Ended |
Ìý |
||||||||||
Ìý |
Ìý |
June 30, 2025 |
Ìý |
Ìý |
June 30, 2024 |
Ìý |
Ìý |
June 30, 2025 |
Ìý |
Ìý |
June 30, 2024 |
Ìý |
||||
Revenues, net |
Ìý |
$ |
74,396 |
Ìý |
Ìý |
$ |
71,556 |
Ìý |
Ìý |
$ |
147,881 |
Ìý |
Ìý |
$ |
144,316 |
Ìý |
Operating costs and expenses: |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Cost of revenues (excluding depreciation and amortization) |
Ìý |
Ìý |
26,364 |
Ìý |
Ìý |
Ìý |
23,738 |
Ìý |
Ìý |
Ìý |
51,851 |
Ìý |
Ìý |
Ìý |
48,355 |
Ìý |
Product development |
Ìý |
Ìý |
12,073 |
Ìý |
Ìý |
Ìý |
12,076 |
Ìý |
Ìý |
Ìý |
24,121 |
Ìý |
Ìý |
Ìý |
24,107 |
Ìý |
Sales and marketing |
Ìý |
Ìý |
11,808 |
Ìý |
Ìý |
Ìý |
11,405 |
Ìý |
Ìý |
Ìý |
23,958 |
Ìý |
Ìý |
Ìý |
23,179 |
Ìý |
General and administrative |
Ìý |
Ìý |
7,398 |
Ìý |
Ìý |
Ìý |
9,556 |
Ìý |
Ìý |
Ìý |
16,066 |
Ìý |
Ìý |
Ìý |
17,868 |
Ìý |
Depreciation and amortization |
Ìý |
Ìý |
10,867 |
Ìý |
Ìý |
Ìý |
10,370 |
Ìý |
Ìý |
Ìý |
21,621 |
Ìý |
Ìý |
Ìý |
20,706 |
Ìý |
Total operating costs and expenses |
Ìý |
Ìý |
68,510 |
Ìý |
Ìý |
Ìý |
67,145 |
Ìý |
Ìý |
Ìý |
137,617 |
Ìý |
Ìý |
Ìý |
134,215 |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Operating income |
Ìý |
Ìý |
5,886 |
Ìý |
Ìý |
Ìý |
4,411 |
Ìý |
Ìý |
Ìý |
10,264 |
Ìý |
Ìý |
Ìý |
10,101 |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Interest income |
Ìý |
Ìý |
958 |
Ìý |
Ìý |
Ìý |
944 |
Ìý |
Ìý |
Ìý |
1,889 |
Ìý |
Ìý |
Ìý |
1,848 |
Ìý |
Other income (expense), net |
Ìý |
Ìý |
23 |
Ìý |
Ìý |
Ìý |
(55 |
) |
Ìý |
Ìý |
(39 |
) |
Ìý |
Ìý |
(107 |
) |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Income before income tax provision |
Ìý |
Ìý |
6,867 |
Ìý |
Ìý |
Ìý |
5,300 |
Ìý |
Ìý |
Ìý |
12,114 |
Ìý |
Ìý |
Ìý |
11,842 |
Ìý |
Income tax provision |
Ìý |
Ìý |
1,478 |
Ìý |
Ìý |
Ìý |
1,132 |
Ìý |
Ìý |
Ìý |
2,393 |
Ìý |
Ìý |
Ìý |
2,448 |
Ìý |
Net income |
Ìý |
$ |
5,389 |
Ìý |
Ìý |
$ |
4,168 |
Ìý |
Ìý |
$ |
9,721 |
Ìý |
Ìý |
$ |
9,394 |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Net income per share: |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Basic |
Ìý |
$ |
0.18 |
Ìý |
Ìý |
$ |
0.14 |
Ìý |
Ìý |
$ |
0.32 |
Ìý |
Ìý |
$ |
0.31 |
Ìý |
Diluted |
Ìý |
$ |
0.18 |
Ìý |
Ìý |
$ |
0.14 |
Ìý |
Ìý |
$ |
0.32 |
Ìý |
Ìý |
$ |
0.31 |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Weighted average shares of common stock outstanding: |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Basic |
Ìý |
Ìý |
30,320 |
Ìý |
Ìý |
Ìý |
30,401 |
Ìý |
Ìý |
Ìý |
30,382 |
Ìý |
Ìý |
Ìý |
30,357 |
Ìý |
Diluted |
Ìý |
Ìý |
30,450 |
Ìý |
Ìý |
Ìý |
30,526 |
Ìý |
Ìý |
Ìý |
30,519 |
Ìý |
Ìý |
Ìý |
30,472 |
Ìý |
Dividends declared per share |
Ìý |
$ |
0.031 |
Ìý |
Ìý |
$ |
0.028 |
Ìý |
Ìý |
$ |
0.062 |
Ìý |
Ìý |
$ |
0.056 |
Ìý |
Ìý HEALTHSTREAM, INC. Condensed Consolidated Balance Sheets (In thousands) (Unaudited) Ìý |
||||||||
Ìý |
Ìý |
June 30, |
Ìý |
Ìý |
December 31, |
Ìý |
||
Ìý |
Ìý |
2025 |
Ìý |
Ìý |
2024 |
Ìý |
||
ASSETS |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Current assets: |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Cash and cash equivalents |
Ìý |
$ |
52,102 |
Ìý |
Ìý |
$ |
59,469 |
Ìý |
Marketable securities |
Ìý |
Ìý |
38,517 |
Ìý |
Ìý |
Ìý |
37,748 |
Ìý |
Accounts and unbilled receivables, net |
Ìý |
Ìý |
31,467 |
Ìý |
Ìý |
Ìý |
35,322 |
Ìý |
Prepaid and other current assets |
Ìý |
Ìý |
22,310 |
Ìý |
Ìý |
Ìý |
20,583 |
Ìý |
Total current assets |
Ìý |
Ìý |
144,396 |
Ìý |
Ìý |
Ìý |
153,122 |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Capitalized software development, net |
Ìý |
Ìý |
44,580 |
Ìý |
Ìý |
Ìý |
43,370 |
Ìý |
Property and equipment, net |
Ìý |
Ìý |
11,914 |
Ìý |
Ìý |
Ìý |
10,741 |
Ìý |
Operating lease right of use assets, net |
Ìý |
Ìý |
16,262 |
Ìý |
Ìý |
Ìý |
17,453 |
Ìý |
Goodwill and intangible assets, net |
Ìý |
Ìý |
240,710 |
Ìý |
Ìý |
Ìý |
246,768 |
Ìý |
Other assets |
Ìý |
Ìý |
42,286 |
Ìý |
Ìý |
Ìý |
39,312 |
Ìý |
Total assets |
Ìý |
$ |
500,148 |
Ìý |
Ìý |
$ |
510,766 |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
LIABILITIES AND SHAREHOLDERS� EQUITY |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Current liabilities: |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Accounts payable, accrued, and other liabilities |
Ìý |
$ |
27,002 |
Ìý |
Ìý |
$ |
31,466 |
Ìý |
Deferred revenue |
Ìý |
Ìý |
88,376 |
Ìý |
Ìý |
Ìý |
84,227 |
Ìý |
Total current liabilities |
Ìý |
Ìý |
115,378 |
Ìý |
Ìý |
Ìý |
115,693 |
Ìý |
Deferred tax liabilities |
Ìý |
Ìý |
15,101 |
Ìý |
Ìý |
Ìý |
14,596 |
Ìý |
Deferred revenue, noncurrent |
Ìý |
Ìý |
1,198 |
Ìý |
Ìý |
Ìý |
1,655 |
Ìý |
Operating lease liability, noncurrent |
Ìý |
Ìý |
15,891 |
Ìý |
Ìý |
Ìý |
17,366 |
Ìý |
Other long-term liabilities |
Ìý |
Ìý |
2,013 |
Ìý |
Ìý |
Ìý |
2,101 |
Ìý |
Total liabilities |
Ìý |
Ìý |
149,581 |
Ìý |
Ìý |
Ìý |
151,411 |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Shareholders� equity: |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Common stock |
Ìý |
Ìý |
235,041 |
Ìý |
Ìý |
Ìý |
252,432 |
Ìý |
Accumulated other comprehensive loss |
Ìý |
Ìý |
(1,278 |
) |
Ìý |
Ìý |
(2,049 |
) |
Retained earnings |
Ìý |
Ìý |
116,804 |
Ìý |
Ìý |
Ìý |
108,972 |
Ìý |
Total shareholders� equity |
Ìý |
Ìý |
350,567 |
Ìý |
Ìý |
Ìý |
359,355 |
Ìý |
Total liabilities and shareholders' equity |
Ìý |
$ |
500,148 |
Ìý |
Ìý |
$ |
510,766 |
Ìý |
Ìý HEALTHSTREAM, INC. Condensed Consolidated Statements of Cash Flows (In thousands) (Unaudited) Ìý |
||||||||
Ìý |
Ìý |
Six Months Ended |
Ìý |
|||||
Ìý |
Ìý |
June 30, |
Ìý |
Ìý |
June 30, |
Ìý |
||
Ìý |
Ìý |
2025 |
Ìý |
Ìý |
2024 |
Ìý |
||
Operating activities: |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Net income |
Ìý |
$ |
9,721 |
Ìý |
Ìý |
$ |
9,394 |
Ìý |
Adjustments to reconcile net income to net cash provided by operating activities: |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Depreciation and amortization |
Ìý |
Ìý |
21,621 |
Ìý |
Ìý |
Ìý |
20,706 |
Ìý |
Stock-based compensation |
Ìý |
Ìý |
1,940 |
Ìý |
Ìý |
Ìý |
2,154 |
Ìý |
Amortization of deferred commissions |
Ìý |
Ìý |
6,017 |
Ìý |
Ìý |
Ìý |
5,956 |
Ìý |
Deferred income taxes |
Ìý |
Ìý |
467 |
Ìý |
Ìý |
Ìý |
(542 |
) |
Provision for credit losses |
Ìý |
Ìý |
391 |
Ìý |
Ìý |
Ìý |
1,802 |
Ìý |
Loss on equity method investments |
Ìý |
Ìý |
107 |
Ìý |
Ìý |
Ìý |
82 |
Ìý |
Other |
Ìý |
Ìý |
(776 |
) |
Ìý |
Ìý |
(746 |
) |
Changes in assets and liabilities: |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Accounts and unbilled receivables |
Ìý |
Ìý |
3,465 |
Ìý |
Ìý |
Ìý |
449 |
Ìý |
Prepaid and other assets |
Ìý |
Ìý |
(10,324 |
) |
Ìý |
Ìý |
(5,569 |
) |
Accounts payable, accrued, and other liabilities |
Ìý |
Ìý |
(4,224 |
) |
Ìý |
Ìý |
(9,282 |
) |
Deferred revenue |
Ìý |
Ìý |
3,692 |
Ìý |
Ìý |
Ìý |
2,985 |
Ìý |
Net cash provided by operating activities |
Ìý |
Ìý |
32,097 |
Ìý |
Ìý |
Ìý |
27,389 |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Investing activities: |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Purchases of marketable securities, net of proceeds |
Ìý |
Ìý |
(27 |
) |
Ìý |
Ìý |
(5,330 |
) |
Proceeds from sale of non-marketable equity investments |
Ìý |
Ìý |
� |
Ìý |
Ìý |
Ìý |
765 |
Ìý |
Purchase of other investments |
Ìý |
Ìý |
(500 |
) |
Ìý |
Ìý |
� |
Ìý |
Purchases of property and equipment |
Ìý |
Ìý |
(3,372 |
) |
Ìý |
Ìý |
(914 |
) |
Payments associated with capitalized software development |
Ìý |
Ìý |
(14,500 |
) |
Ìý |
Ìý |
(13,552 |
) |
Net cash used in investing activities |
Ìý |
Ìý |
(18,399 |
) |
Ìý |
Ìý |
(19,031 |
) |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Financing activities: |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Taxes paid related to net settlement of equity awards |
Ìý |
Ìý |
(1,075 |
) |
Ìý |
Ìý |
(861 |
) |
Payment of cash dividends |
Ìý |
Ìý |
(1,890 |
) |
Ìý |
Ìý |
(1,700 |
) |
Repurchases of common stock |
Ìý |
Ìý |
(18,121 |
) |
Ìý |
Ìý |
� |
Ìý |
Net cash used in financing activities |
Ìý |
Ìý |
(21,086 |
) |
Ìý |
Ìý |
(2,561 |
) |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Ìý |
Effect of exchange rate changes on cash and cash equivalents |
Ìý |
Ìý |
21 |
Ìý |
Ìý |
Ìý |
1 |
Ìý |
Net (decrease) increase in cash and cash equivalents |
Ìý |
Ìý |
(7,367 |
) |
Ìý |
Ìý |
5,798 |
Ìý |
Cash and cash equivalents at beginning of period |
Ìý |
Ìý |
59,469 |
Ìý |
Ìý |
Ìý |
40,333 |
Ìý |
Cash and cash equivalents at end of period |
Ìý |
$ |
52,102 |
Ìý |
Ìý |
$ |
46,131 |
Ìý |
Ìý Reconciliation of GAAP to Non-GAAP Financial Measures(1) Operating Results Summary (In thousands) (Unaudited) Ìý |
||||||||||||||||
Ìý |
Ìý |
Three Months Ended June 30, |
Ìý |
Ìý |
Six Months Ended June 30, |
Ìý |
||||||||||
Ìý |
Ìý |
2025 |
Ìý |
Ìý |
2024 |
Ìý |
Ìý |
2025 |
Ìý |
Ìý |
2024 |
Ìý |
||||
GAAP net income |
Ìý |
$ |
5,389 |
Ìý |
Ìý |
$ |
4,168 |
Ìý |
Ìý |
$ |
9,721 |
Ìý |
Ìý |
$ |
9,394 |
Ìý |
Interest income |
Ìý |
Ìý |
(958 |
) |
Ìý |
Ìý |
(944 |
) |
Ìý |
Ìý |
(1,889 |
) |
Ìý |
Ìý |
(1,848 |
) |
Interest expense |
Ìý |
Ìý |
25 |
Ìý |
Ìý |
Ìý |
25 |
Ìý |
Ìý |
Ìý |
50 |
Ìý |
Ìý |
Ìý |
49 |
Ìý |
Income tax provision |
Ìý |
Ìý |
1,478 |
Ìý |
Ìý |
Ìý |
1,132 |
Ìý |
Ìý |
Ìý |
2,393 |
Ìý |
Ìý |
Ìý |
2,448 |
Ìý |
Stock-based compensation expense |
Ìý |
Ìý |
836 |
Ìý |
Ìý |
Ìý |
1,094 |
Ìý |
Ìý |
Ìý |
1,940 |
Ìý |
Ìý |
Ìý |
2,154 |
Ìý |
Depreciation and amortization |
Ìý |
Ìý |
10,867 |
Ìý |
Ìý |
Ìý |
10,370 |
Ìý |
Ìý |
Ìý |
21,621 |
Ìý |
Ìý |
Ìý |
20,706 |
Ìý |
Adjusted EBITDA |
Ìý |
$ |
17,637 |
Ìý |
Ìý |
$ |
15,845 |
Ìý |
Ìý |
$ |
33,836 |
Ìý |
Ìý |
$ |
32,903 |
Ìý |
Ìý (1) This press release presents adjusted EBITDA, which is a non-GAAP financial measure used by management in analyzing its financial results and ongoing operational performance. |
Ìý Reconciliation of GAAP to Non-GAAP Financial Measures Financial Outlook for 2025 (In thousands) (Unaudited) Ìý |
||||||||
Ìý |
Ìý |
Low |
Ìý |
Ìý |
High |
Ìý |
||
Net income |
Ìý |
$ |
19,500 |
Ìý |
Ìý |
$ |
22,400 |
Ìý |
Interest income |
Ìý |
Ìý |
(3,300 |
) |
Ìý |
Ìý |
(3,500 |
) |
Interest expense |
Ìý |
Ìý |
100 |
Ìý |
Ìý |
Ìý |
100 |
Ìý |
Income tax provision |
Ìý |
Ìý |
5,200 |
Ìý |
Ìý |
Ìý |
6,000 |
Ìý |
Stock-based compensation expense |
Ìý |
Ìý |
4,000 |
Ìý |
Ìý |
Ìý |
4,300 |
Ìý |
Depreciation and amortization |
Ìý |
Ìý |
43,000 |
Ìý |
Ìý |
Ìý |
43,200 |
Ìý |
Adjusted EBITDA |
Ìý |
$ |
68,500 |
Ìý |
Ìý |
$ |
72,500 |
Ìý |
This press release includes certain forward-looking statements (statements other than solely with respect to historical fact), including statements regarding expectations for financial performance for 2025 and our quarterly dividend policy, that involve risks and uncertainties regarding HealthStream. These statements are based upon management’s beliefs, as well as assumptions made by and data currently available to management. This information has been, or in the future may be, included in reliance on the “safe harbor� provisions of the Private Securities Litigation Reform Act of 1995. The Company cautions that forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements to be materially different from future results, performance, or achievements expressed or implied by the forward-looking statements, including as a result of negative economic conditions, changes in
View source version on businesswire.com:
Scott A. Roberts
Chief Financial Officer
(615) 301-3182
[email protected]
Media:
Mollie Condra, Ph.D.
Head, Investor Relations & Communications
(615) 301-3237
[email protected]
Source: HealthStream, Inc.